In patients with post-bariatric hypoglycemia (PBH), pramlintide does not affect glycemic or insulin responses, satiety, or dumping scores during mixed-meal tolerance tests (MMTT). Additionally, it does not alter glycemic fluctuations or reduce low sensor glucose levels in outpatient settings. This evidence concerns the gene INS and Hypoglycemia.